Abstract Library

#1073 The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care

Introduction: NETs remain a relatively rare malignancy. Clinical trials are often hindered by the limited number of patients available and thus registries provide important information about patterns of care and patient outcomes.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Price T

Authors: Price T, Pavlakis N, Karapetis C, Michael M, Singhal N,

Keywords: Registry,

#938 Clinical Characteristics of 144 patients (pts) Included in a Multidisciplinary Group, with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) G2 (WHO 2010). Grupo Argentum.

Introduction: Neuroendocrine tumors (NETs) G2 of the digestive tract are a heterogeneous group of tumors. Several treatment options including chemotherapy and target therapy are used, but there is a lack of prospective trials assessing the role of predictive factors in this population.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: OConnor J

Authors: O'Connor J, Pesce V, Bestanti C, Marmissolle F, Price P,

Keywords: neuroendocrine tumor, G2, survival,

#616 Assessment of DNA Double-Strand Breaks in Blood Lymphocytes after Whole-Body Radiation Exposure in Patients with Neuroendocrine Tumors Undergoing 177Lu-Octreotate Therapy

Introduction: Peptide receptor radionuclide therapy using somatostatin receptor-binding peptides, such as 177Lu-Octreotate (LuTate), has been clinically proven to be effective in treating patients with inoperable neuroendocrine tumors. Despite the rather high radiation exposure, only few side effects have been reported. However, blood cells are very sensitive to radiation. Therefore, it is important to determine how much radiation they received. Recently, the detection by immunofluorescence of the phosphorylation of the histone variant H2AX (γ‐H2AX) has been established as a reliable and sensitive technique to monitor DNA double-strand breaks (DSBs) in blood lymphocytes.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Denoyer D

Authors: Denoyer D, Martin O, Jackson P, Johnston V, Hicks R,

Keywords: 177Lu-Octreotate, γ‐H2AX, DNA damage,